The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TFX | -44.22% | -66.44% | -19.6% | +74,825% |
| S&P | +12.65% | +91.73% | +13.89% | +6,901% |
Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.
The newest component of the index is a medical device maker that also likes to make deals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $913.02M | 19.4% |
| Gross Profit | $452.24M | 5.1% |
| Gross Margin | 40.93% | -15.3% |
| Market Cap | $5.41B | -53.6% |
| Market Cap / Employee | $0.38M | 0.0% |
| Employees | 14.1K | -2.8% |
| Net Income | -$408.88M | -468.6% |
| EBITDA | $112.65M | -47.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $368.70M | 51.6% |
| Accounts Receivable | $592.65M | 26.0% |
| Inventory | 802.5 | 25.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.67B | 51.3% |
| Short Term Debt | $100.00M | 3.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.27% | -7.4% |
| Return On Invested Capital | 5.52% | -1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $77.69M | -63.0% |
| Operating Free Cash Flow | $107.63M | -53.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 49.06 | 124.74 | 43.43 | 28.12 | -25.53% |
| Price to Book | 1.84 | 1.55 | 1.29 | 1.27 | -50.14% |
| Price to Sales | 2.71 | 2.10 | 1.74 | 1.66 | -56.61% |
| Price to Tangible Book Value | -10.85 | -10.67 | -6.75 | -8.51 | -47.88% |
| Price to Free Cash Flow TTM | 18.52 | 15.17 | 15.82 | 26.10 | -13.12% |
| Enterprise Value to EBITDA | 44.86 | 40.66 | 28.74 | 68.56 | 10.35% |
| Free Cash Flow Yield | 5.4% | 6.6% | 6.3% | 3.8% | 15.10% |
| Return on Equity | 1.6% | 3.5% | 4.4% | -7.9% | -245.91% |
| Total Debt | $1.77B | $2.00B | $2.00B | $2.77B | 48.77% |
No podcast episodes available.
TFX earnings call for the period ending September 30, 2021.
TFX earnings call for the period ending July 30, 2021.
TFX earnings call for the period ending March 28, 2021.
TFX earnings call for the period ending February 26, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
